Loading...
•
Jun 30
RAPT Q2 2025 Earnings Report
RAPT Therapeutics reported its financial results for the second quarter and six months ended June 30, 2025.
Key Takeaways
RAPT Therapeutics reported a net loss of $17.6 million for the second quarter of 2025, a significant improvement compared to a net loss of $27.7 million in the same period last year. This reduction in loss was primarily driven by a decrease in research and development expenses. The company ended the quarter with $168.9 million in cash and cash equivalents and marketable securities.
Net loss for Q2 2025 was $17.6 million, a substantial decrease from $27.7 million in Q2 2024.
Research and development expenses decreased to $12.3 million in Q2 2025 from $22.6 million in Q2 2024, mainly due to reduced costs for zelnecirnon and tivumecirnon development.
General and administrative expenses slightly increased to $7.2 million in Q2 2025 from $6.7 million in Q2 2024.
The company maintained a strong cash position with $168.9 million in cash and cash equivalents and marketable securities as of June 30, 2025.
RAPT
RAPT
Forward Guidance
RAPT Therapeutics anticipates several key catalysts in the second half of 2025, including the initiation of a Phase 2b trial for RPT904 in food allergy and topline results from Jemincare's Phase 2 trials of RPT904 in CSU and asthma.
Positive Outlook
- On track to initiate Phase 2b trial of RPT904 in food allergy later this year.
- On track with partner Jemincare to report topline results from Phase 2 trials of RPT904 in CSU and asthma in the second half of this year.
- Continued advancement of the next-generation CCR4 pipeline.
- Strengthened team with experienced drug developer Jessica Savage.
- Board of directors strengthened with appointments of industry veterans Drs. Scott Braunstein and Ashley Dombkowski.
Challenges Ahead
- Unexpected or unfavorable safety or efficacy data observed during clinical studies could impact results.
- Preliminary data and trends may not be predictive of future data or results or may not demonstrate safety or efficacy or lead to regulatory approval.
- Reliance on partners and other third parties introduces risks.
- Clinical trial site activation or enrollment rates may be lower than expected.
- Unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including ongoing overseas conflicts, tariffs, trade tensions, fluctuations in inflation and interest rates, and other economic uncertainty).